These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1052 related articles for article (PubMed ID: 20060365)

  • 1. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.
    Figueroa ME; Lugthart S; Li Y; Erpelinck-Verschueren C; Deng X; Christos PJ; Schifano E; Booth J; van Putten W; Skrabanek L; Campagne F; Mazumdar M; Greally JM; Valk PJ; Löwenberg B; Delwel R; Melnick A
    Cancer Cell; 2010 Jan; 17(1):13-27. PubMed ID: 20060365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CBFB-MYH11 hypomethylation signature and PBX3 differential methylation revealed by targeted bisulfite sequencing in patients with acute myeloid leukemia.
    Hájková H; Fritz MH; Haškovec C; Schwarz J; Šálek C; Marková J; Krejčík Z; Dostálová Merkerová M; Kostečka A; Vostrý M; Fuchs O; Michalová K; Cetkovský P; Beneš V
    J Hematol Oncol; 2014 Sep; 7():66. PubMed ID: 25266220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia.
    Alvarez S; Suela J; Valencia A; Fernández A; Wunderlich M; Agirre X; Prósper F; Martín-Subero JI; Maiques A; Acquadro F; Rodriguez Perales S; Calasanz MJ; Roman-Gómez J; Siebert R; Mulloy JC; Cervera J; Sanz MA; Esteller M; Cigudosa JC
    PLoS One; 2010 Aug; 5(8):e12197. PubMed ID: 20808941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia.
    Xu ZJ; Ma JC; Zhou JD; Wen XM; Yao DM; Zhang W; Ji RB; Wu DH; Tang LJ; Deng ZQ; Qian J; Lin J
    J Transl Med; 2019 Mar; 17(1):102. PubMed ID: 30922328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia.
    Shen Y; Zhu YM; Fan X; Shi JY; Wang QR; Yan XJ; Gu ZH; Wang YY; Chen B; Jiang CL; Yan H; Chen FF; Chen HM; Chen Z; Jin J; Chen SJ
    Blood; 2011 Nov; 118(20):5593-603. PubMed ID: 21881046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of gene expression and DNA-methylation profiles improves molecular subtype classification in acute myeloid leukemia.
    Taskesen E; Babaei S; Reinders MM; de Ridder J
    BMC Bioinformatics; 2015; 16 Suppl 4(Suppl 4):S5. PubMed ID: 25734246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks.
    Deneberg S; Guardiola P; Lennartsson A; Qu Y; Gaidzik V; Blanchet O; Karimi M; Bengtzén S; Nahi H; Uggla B; Tidefelt U; Höglund M; Paul C; Ekwall K; Döhner K; Lehmann S
    Blood; 2011 Nov; 118(20):5573-82. PubMed ID: 21960591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DOK6 promoter methylation serves as a potential biomarker affecting prognosis in de novo acute myeloid leukemia.
    Sun GK; Tang LJ; Zhou JD; Xu ZJ; Yang L; Yuan Q; Ma JC; Liu XH; Lin J; Qian J; Yao DM
    Cancer Med; 2019 Oct; 8(14):6393-6402. PubMed ID: 31486300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy.
    Hiller JK; Schmoor C; Gaidzik VI; Schmidt-Salzmann C; Yalcin A; Abdelkarim M; Blagitko-Dorfs N; Döhner K; Bullinger L; Duyster J; Lübbert M; Hackanson B
    Ann Hematol; 2017 Apr; 96(4):559-565. PubMed ID: 28058491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
    Becker H; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Margeson D; Whitman SP; Wu YZ; Schwind S; Paschka P; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
    J Clin Oncol; 2010 Feb; 28(4):596-604. PubMed ID: 20026798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia.
    Balgobind BV; Van den Heuvel-Eibrink MM; De Menezes RX; Reinhardt D; Hollink IH; Arentsen-Peters ST; van Wering ER; Kaspers GJ; Cloos J; de Bont ES; Cayuela JM; Baruchel A; Meyer C; Marschalek R; Trka J; Stary J; Beverloo HB; Pieters R; Zwaan CM; den Boer ML
    Haematologica; 2011 Feb; 96(2):221-30. PubMed ID: 20971820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel hierarchical prognostic model of AML solely based on molecular mutations.
    Grossmann V; Schnittger S; Kohlmann A; Eder C; Roller A; Dicker F; Schmid C; Wendtner CM; Staib P; Serve H; Kreuzer KA; Kern W; Haferlach T; Haferlach C
    Blood; 2012 Oct; 120(15):2963-72. PubMed ID: 22915647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic Silencing of Eyes Absent 4 Gene by Acute Myeloid Leukemia 1-Eight-twenty-one Oncoprotein Contributes to Leukemogenesis in t(8;21) Acute Myeloid Leukemia.
    Huang S; Jiang MM; Chen GF; Qian K; Gao HH; Guan W; Shi JL; Liu AQ; Liu J; Wang BH; Li YH; Yu L
    Chin Med J (Engl); 2016 Jun; 129(11):1355-62. PubMed ID: 27231175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined testing for CCAAT/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features.
    Szankasi P; Ho AK; Bahler DW; Efimova O; Kelley TW
    Leuk Res; 2011 Feb; 35(2):200-7. PubMed ID: 20970189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of DNA methylation to predict outcome in acute myeloid leukemia by use of xMELP.
    Wertheim GB; Smith C; Luskin M; Rager A; Figueroa ME; Carroll M; Master SR
    Clin Chem; 2015 Jan; 61(1):249-58. PubMed ID: 25348669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypermethylation of the GATA binding protein 4 (GATA4) promoter in Chinese pediatric acute myeloid leukemia.
    Tao YF; Fang F; Hu SY; Lu J; Cao L; Zhao WL; Xiao PF; Li ZH; Wang NN; Xu LX; Du XJ; Sun LC; Li YH; Li YP; Xu YY; Ni J; Wang J; Feng X; Pan J
    BMC Cancer; 2015 Oct; 15():756. PubMed ID: 26490736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and Biological Implications of Mutational Spectrum in Acute Myeloid Leukemia of FAB Subtypes M0 and M1.
    Cheng Z; Dai Y; Pang Y; Jiao Y; Zhao H; Wu S; Zhang L; Zhang Y; Wang X; Wang L; Ma D; Qin T; Hu N; Zhang Y; Hu K; Zhang Q; Shi J; Fu L
    Cell Physiol Biochem; 2018; 47(5):1853-1861. PubMed ID: 29961066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients.
    Lauber C; Correia N; Trumpp A; Rieger MA; Dolnik A; Bullinger L; Roeder I; Seifert M
    Sci Rep; 2020 Jul; 10(1):12761. PubMed ID: 32728112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AML1-ETO triggers epigenetic activation of early growth response gene l, inducing apoptosis in t(8;21) acute myeloid leukemia.
    Fu L; Huang W; Jing Y; Jiang M; Zhao Y; Shi J; Huang S; Xue X; Zhang Q; Tang J; Dou L; Wang L; Nervi C; Li Y; Yu L
    FEBS J; 2014 Feb; 281(4):1123-31. PubMed ID: 24314118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen.
    Xu Q; Li Y; Jing Y; Lv N; Wang L; Li Y; Yu L
    Int J Cancer; 2020 Mar; 146(5):1457-1467. PubMed ID: 31344264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.